Sector News

Valeant can have Zoetis, Bayer says. We have our hands full already

June 30, 2015
Life sciences
Whether animal health leader Zoetis receives any more buyout offers after Valeant’s reported approach remains to be seen. But if it does, Bayer’s leaders insist a competing bid won’t be coming from them.
 
As the German pharma’s management told Bernstein analyst Ronny Gal last week, it weighed buying Zoetis against picking up Merck’s OTC unit last year–and it decided to go after the latter, which it agreed to snag last May for $14.2 billion.
 
Bayer has long considered beefing up its animal health ops, but as CEO Marijn Dekkers put it last month, “it hasn’t happened with us yet.” The company considered snapping up Novartis’ veterinary business before Eli Lilly grabbed it last year, and it also contemplated a move for Zoetis back before Pfizer made clear that it intended to spin the business off. Before Dekkers’ time, now-Chairman Werner Wenning bid unsuccessfully for Schering-Plough’s animal health unit.
 
So when the Leverkeusen-based drugmaker announced plans to divest its plastics business–a move that would generate some extra dough–analysts speculated this could finally be the time, and speculators pegged $25 billion company Zoetis as a likely target.
 
Bayer has already gone on somewhat of an M&A spree lately, though, which would make a large acquisition right now “challenging,” Gal wrote. Shortly before inking the Merck consumer health pact, Bayer bought up another OTC company in China’s Dihon Pharmaceutical. All told, it’s got $21 billion in debt and $13.5 billion in pension liabilities and thus “is a bit starched financially right now,” Gal said.
 
Canada’s Valeant, though, hasn’t let its recent deals stop it from pursuing Zoetis, according to The Wall Street Journal. The serial acquirer–whose former deal partner, Bill Ackman, has been leveraging investor pressure on Zoetis since acquiring a stake last fall–has approached Zoetis about a potential buyout, the newspaper reported last week.
 
By Carly Helfand  
 

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend